Septerna to Present at TD Cowen 45th Annual Health Care Conference

Rhea-AI Summary

Septerna (Nasdaq: SEPN), a biotechnology company focused on G protein-coupled receptor (GPCR) drug discovery, has announced its participation in an upcoming investor event. The company's CEO and Co-founder, Jeffrey Finer, M.D., Ph.D., will deliver a presentation at the TD Cowen 45th Annual Health Care Conference in Boston.

The presentation is scheduled for Wednesday, March 5, 2025, at 10:30 a.m. ET. This conference appearance represents an opportunity for Septerna to showcase its innovative GPCR drug discovery platform to the investment community.

News Market Reaction – SEPN

+3.26%

+3.26% Session move

In the trading session that priced this news, SEPN gained 3.26%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that Jeffrey Finer, M.D., Ph.D., Chief Executive Officer and Co-founder of Septerna, will present at the TD Cowen 45^th Annual Health Care Conference on Wednesday, March 5, 2025, at 10:30 a.m. ET in Boston.

About Septerna
Septerna, Inc. is a biotechnology company pioneering a new era of GPCR drug discovery powered by its proprietary Native Complex Platform™. Its industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of its deep pipeline of oral small molecule product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Septerna was launched by preeminent drug discovery company builders and scientific leaders in the biochemistry, structural biology, and pharmacology of GPCRs. For more information, please visit www.septerna.com.

Investor Contact:
Renee Leck
THRUST Strategic Communications
renee@thrustsc.com

FAQ

When is Septerna (SEPN) presenting at the TD Cowen Healthcare Conference 2025?

Septerna will present on Wednesday, March 5, 2025, at 10:30 a.m. ET in Boston.

Who will represent Septerna (SEPN) at the TD Cowen Healthcare Conference?

Jeffrey Finer, M.D., Ph.D., Chief Executive Officer and Co-founder of Septerna, will present at the conference.

What is Septerna's (SEPN) main focus in drug discovery?

Septerna specializes in G protein-coupled receptor (GPCR) drug discovery.

Which major healthcare conference is Septerna (SEPN) participating in March 2025?

Septerna is participating in the TD Cowen 45th Annual Health Care Conference in Boston.